Data Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting

FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that a podium talk and multiple abstracts featuring data for the company’s NeXT Personal® whole genome-based, tumor-informed assay for ultra-sensitive ctDNA detection will be presented at the American Association for Cancer Research (AACR) Annual Meeting, taking place in San Diego, California, April 5-10, 2024.

“Personalis is excited to present data showing our ultra-sensitive MRD test, NeXT Personal, has the potential to find recurrent cancer earlier and monitor response in late-stage cancer patients receiving immunotherapy,” said Dr. Richard Chen, Chief Medical Officer and Executive Vice President, R&D at Personalis.

Personalis will be sharing progress with collaborative research findings as well as the latest clinical results related to NeXT Personal. Highlights include:

• Mini-symposium (Liquid Biopsy): Ultra-sensitive ctDNA detection predicts response to immune checkpoint inhibition in advanced melanoma patients
  • Speaker: Dr. Christoffer Gebhardt
  • Date & Time: Tuesday, April 9, 2:55 PM - 3:10 PM
  • Location: Room 6 CF - Upper Level - Convention Center

ctDNA dynamics detected with NeXT Personal were predictive of patient response and outcomes in melanoma patients receiving immunotherapy; over a third of ctDNA detections were in the ultra-sensitive range (